期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

全球视角下药品风险分担协议政策分析 被引量：9

下载PDF
导出
摘要 通过文献研究和比较研究,分析全球视角下药品风险分担协议的起源、概念、分类、典型协议类型、优劣,提出我国应加强卫生技术评估在新药补偿中的应用,明确风险分担协议实施条件,并逐步开展基于财务和结局的风险分担协议,以期对我国药品谈判工作提供借鉴和指导。
作者 常峰 崔鹏磊 张舰云 夏强
机构地区 中国药科大学国际医药商学院
出处 《卫生经济研究》 北大核心 2016年第8期39-44,共6页
关键词 风险分担协议 药品价格谈判 价量协议 绩效连结补偿 实证发展补偿
分类号 R19 [医药卫生—卫生事业管理]
  • 相关文献

参考文献15

  • 1de Pouvourville G. Risk-sharing agreements for innovative drugs[J]. The European Journal of Health E- conomics, 2006, 7(3): 155-157.
  • 2何建志.全民健康保险价量协议法律问题分析[J].台大法学论丛,2014,43(2):381-417.
  • 3Ethgen O. Risk-sharing: The Need to Think Differently [EB/OL]. http://www.ispor.org/news/articles/ May -June2011/Risk -sharing -The -Need -to -Think - Differently.asp, 2011.
  • 4Adamski J, Godman B, et al. Risk sharing ar- rangements for pharmaceuticals: potential considera- tions and recommendations for European payers [J]. BMC health services research, 2010, 10(1): 153.
  • 5Towse A, Garrison Jr L P. Can't get no satis- faction? Will pay for performance help? [J]. Pharma- coeconomics, 2010, 28(2): 93-102.
  • 6Klemp M, Frznsdal K B, Facey K. What princi- ples should govern the use of managed entry agree- ments? [J]. International journal of technology assess- merit in health care, 2011, 27(1): 77-83.
  • 7Carlson J J, Sullivan S D, Garrison L P, et al. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between heahhcare payers and manufacturers [J]. Health policy, 2010, 96(3): 179-190.
  • 8Garrison L P, Towse A, Briggs A, et al. Perfor- mance-based risk-sharing arrangements--good prac- tices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force [J]. Value in Health, 2013, 16(5): 703-719.
  • 9Morel T, Arickx F, Befrits G, et al. Reconciling uncertainty of costs and outcomes with the need for ac- cess to orphan medicinal products: a comparative study of managed entry agreements across seven European countries[J]. Orphanet J Rare Dis, 2013, 8: 198.
  • 10林苡竹,陈文.青岛城镇大病医疗救助项目的政策分析[J].中国卫生资源,2015,18(3):203-207. 被引量：11

二级参考文献38

  • 1Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers[ J ]. BMC Health Serv Res,2010, 10: 153.
  • 2McCabe C, Bergmann L, Bosanquet N, et al. Market and patient access to new oncology products in Europe: a current, muhidisciplinary perspective [ J ]. Ann Oncol, 2009, 20 ( 3 ): 403-412.
  • 3Fojo T, Grady C. How much is life worth: cetuximab, non-smaU cell lung cancer, and the S440 billion question[ J ]. J Natl Cancer Inst, 2009, 101: 1044-1048.
  • 4Guirgis HM. Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?[ J ]. J Oncol Pract, 2012, 8( 4 ): 224-230.
  • 5Carlson JJ, Sullivan SD, Garrison LP, et al. Linking payment to health outcomes: a taxonomy and examination of performance- based reimbursement schemes between health care payers and manufacturers[ J ]. Health Policy, 2010, 96( 3 ): 179-190.
  • 6Vogler S, Zimmermann N, Habl C, et al. Discounts and rebates granted to public payers for medicines in European countries [ J ]. Southern Med Rev, 2012, 5( 1 ): 38-46.
  • 7Couhon L, Annemans L, Carter R, et al. Outcomes-based risk- sharing schemes: is there a potential rule in the Asia-Pacific markets?[ J ]. Health Out Res Med, 2012, 3( 4 ): c205-219.
  • 8青岛市人力资源和社会保障局.关于建立城镇大病医疗救助制度的意见(青政办字[2012]92号)[EB/OL].(2012-06-29).http: //www.qdhrss.gov.cn/pages/zczs/zcfgldbszcfg/55475.html.
  • 9Louis P, Garrison Jr, Towse A, et al. Performance-based risk- sharing arrangements--good practices for design, implementation, and evaluation: report of the ISPOR good practice for performance- based risk-sharing arrangements task force [J]. Value Health, 2013( 16): 703-719.
  • 10Navarria A, Drago V, Gozzo L, et al. Do the current performance- based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure [ J ]. Value Health, 2015, 18( 1 ): 131-136.

共引文献38

同被引文献34

引证文献9

二级引证文献32

卫生经济研究
2016年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部